Re-Purposing FDA-Approved Drugs for Opioid Use Disorder
Bibliographic Data
| ID | 21645677 |
|---|---|
| Authors | Krishna Patel (0009-0009-7963-0518, Penn State College of Medicine), David Waldron (0000-0002-0972-5935, Penn State College of Medicine), Nicholas Graziane (0000-0002-7055-7029, Penn State College of Medicine, corresponding author) |
| Year | 2023 |
| Volume | 58 |
| Issue | 13 |
| Pages | 1751-1760 |
| Publication date | 2023-11-10 |
| Peer Reviewed | Yes |
| Open Access | No |
| Type | ARTICLE |
| Venue | Substance Use & Misuse (JOURNAL) |
| Journal identifiers | ISSN: 1082-6084 • E-ISSN: 1532-2491 |
| Publisher | Informa UK Limited (PUBLISHER • GB) |
| DOI | 10.1080/10826084.2023.2247071 |
| PMID | 37584436 |
| OpenAlex | W4385850994 |
| Language | EN |
| References cited | 67 |
OBJECTIVE: To investigate FDA-approved drugs prescribed for unrelated diseases or conditions that promote remission in subjects diagnosed with opioid use disorder (OUD). METHODS: This was a retrospective observational study utilizing the TriNetX electronic medical record data. Subjects between 18 and 65 years old were included in this study. First, a drug screen was employed to identify medications used for chronic illness that are associated with OUD remission. Based on Fisher's exact test for significance, 28 of 101 medications were selected for further analysis. Positive (buprenorphine/methadone) and negative controls (benazepril) were included in the analysis. Medications were analyzed in the absence and presence of buprenorphine or methadone, two medications used to treat OUD, to identify the likelihood of OUD remission up to one year following the index event. RESULTS: We identify 8 medications (prazosin, propranolol, lithium carbonate, olanzapine, quetiapine, bupropion, citalopram, and escitalopram) that may be useful for increasing remission in OUD in the absence of buprenorphine or methadone. Additionally, our results identify psychiatric medications that when taken alongside buprenorphine and methadone improve remission rates. CONCLUSION: These results provide medication options that may be useful in treating OUD as well as integrated therapies to treat comorbid mental illness
Buprenorphine · Methadone · Olanzapine · Opioid · Opioid use disorder · Psychiatry · Quetiapine · Forensic Toxicology and Drug Analysis · Medicine · Opioid Use Disorder Treatment · Substance Abuse Treatment and Outcomes · Internal Medicine
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Co-occurring substance use and mental disorders among adults with opioid use disorder
Increases in Drug and Opioid Overdose Deaths — United States, 2000–2014
Retention in medication-assisted treatment for opiate dependence
Sex and gender differences in substance use disorders
Co-occurring substance abuse and mental health problems among homeless persons
Association between homelessness and opioid overdose and opioid-related hospital admissions/emergency department visits
| Citation velocity | historical |
|---|---|
| Highly cited | No |